{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:11:04Z","timestamp":1792095064286,"version":"4.4.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2025289"],"award-info":[{"award-number":["2025289"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1195460"],"award-info":[{"award-number":["1195460"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R33-AG057289 and R01-AG070047-01"],"award-info":[{"award-number":["R33-AG057289 and R01-AG070047-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Psychotropic polypharmacy is common, increasing, and associated with higher risks of adverse effects, hospitalisations and mortality. This study aimed to explore the attitudes and beliefs of people receiving inpatient mental health care toward deprescribing (<jats:italic>discontinuing a medication when the current or potential risk outweighs the current or potential benefit<\/jats:italic>) and determine any patient characteristics associated with these attitudes and beliefs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A cross-sectional survey of patients admitted to two open acute psychiatric inpatient units was conducted over a 6-month period in the Australian metropolitan city of Adelaide. Individuals were eligible to participate regardless of their reason for admission, if they were at least 18 years old and able to converse, read and write in English, and provide informed consent. Participant characteristics and responses to the validated revised Patients\u2019 Attitudes Towards Deprescribing (rPATD) questionnaire were collected. The rPATD includes questions grouped into four factors: (i) perceived burden of medications, (ii) involvement in medication management, (iii) belief in appropriateness of medications, and (iv) concerns about stopping, plus two global questions. Participants were encouraged to think about medications that they use for their mental health conditions when completing the questionnaire.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>One hundred participants were recruited, with a mean age of 41.6 (SD\u2009=\u200913.7). 65% of participants agreed that they would be willing to stop one or more of their psychotropic medications if their doctor said it was possible. In a binary logistic regression model, willingness to have a medication deprescribed was mostly strongly predicted by Involvement factor score (odds ratio [OR]\u2009=\u20095.92, 95% confidence interval [CI]\u2009=\u20092.10-15-16.70, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>A majority of participants were open to having one or more medication deprescribed. When medically justified, mental health professionals should feel comfortable initiating conversations about deprescribing to understand patient attitudes and preferences, fostering shared decision-making for psychotropic medication management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial number<\/jats:title>\n            <jats:p>Not applicable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12888-025-06717-3","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T18:52:17Z","timestamp":1742583137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Attitudes of Australian patients receiving inpatient mental health care towards deprescribing: a cross-sectional survey"],"prefix":"10.1186","volume":"25","author":[{"given":"Rachel","family":"Law","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aili V","family":"Langford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Reeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"6717_CR1","unstructured":"World Health Organization (WHO). & United Nations (UN) Mental health, human rights and legislation: guidance and practice. 2023."},{"issue":"5","key":"6717_CR2","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamainternmed.2015.0324","volume":"175","author":"IA Scott","year":"2015","unstructured":"Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827\u201334.","journal-title":"JAMA Intern Med"},{"key":"6717_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2016.12.021","volume":"38","author":"E Reeve","year":"2017","unstructured":"Reeve E, Thompson W, Farrell B, Deprescribing. A narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. Eur J Intern Med. 2017;38:3\u201311.","journal-title":"Eur J Intern Med"},{"key":"6717_CR4","doi-asserted-by":"crossref","unstructured":"Kelley CJ, Niznik JD, Ferreri SP, Schlusser C, Armistead LT, Hughes TD et al. Patient perceptions of opioids and benzodiazepines and attitudes toward deprescribing. Drugs Aging. 2023;40(12):1113\u201322.","DOI":"10.1007\/s40266-023-01071-z"},{"issue":"2","key":"6717_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.5694\/mja2.52002","volume":"219","author":"AV Langford","year":"2023","unstructured":"Langford AV, Lin CCW, Bero L, Blyth FM, Doctor J, Holliday S, et al. Clinical practice guideline for deprescribing opioid analgesics: summary of recommendations. Med J Aust. 2023;219(2):80\u20139.","journal-title":"Med J Aust"},{"issue":"8","key":"6717_CR6","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1176\/appi.ps.201500359","volume":"67","author":"S Gupta","year":"2016","unstructured":"Gupta S, Cahill JD. A prescription for deprescribing in psychiatry. Psychiatr Serv. 2016;67(8):904\u20137.","journal-title":"Psychiatr Serv"},{"issue":"2","key":"6717_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/ijnp\/pyz068","volume":"23","author":"SK Lin","year":"2020","unstructured":"Lin SK. Antipsychotic polypharmacy: A dirty little secret or a fashion?? Int J Neuropsychopharmacol. 2020;23(2):125\u201331.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"6717_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1517\/14740338.2012.683523","volume":"11","author":"JA Gallego","year":"2012","unstructured":"Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11(4):527\u201342.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"6717_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bcpt.13384","volume":"126","author":"L Baandrup","year":"2020","unstructured":"Baandrup L. Polypharmacy in schizophrenia. Basic Clin Pharmacol Toxicol. 2020;126(3):183\u201392.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"6717_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archgenpsychiatry.2009.175","volume":"67","author":"R Mojtabai","year":"2010","unstructured":"Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67(1):26\u201336.","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"6717_CR11","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1111\/bcp.13369","volume":"83","author":"J Brett","year":"2017","unstructured":"Brett J, Daniels B, Karanges EA, Buckley NA, Schneider C, Nassir A, et al. Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. Br J Clin Pharmacol. 2017;83(11):2581\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"6717_CR12","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S2215-0366(24)00314-6","volume":"11","author":"M H\u00f8jlund","year":"2024","unstructured":"H\u00f8jlund M, K\u00f6hler-Forsberg O, Gregersen AT, Rohde C, Mellentin AI, Anh\u00f8j SJ, et al. Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis. Lancet Psychiatry. 2024;11(12):975\u201389.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"6717_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","volume":"138","author":"JA Gallego","year":"2012","unstructured":"Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138(1):18\u201328.","journal-title":"Schizophr Res"},{"issue":"4","key":"6717_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/0269881113477709","volume":"27","author":"MW van Lochmann","year":"2013","unstructured":"van Lochmann MW, Gijsman HJ, Zitman FG. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. J Psychopharmacol. 2013;27(4):327\u201336.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"6717_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1017\/S1461145703004012","volume":"7","author":"T Suzuki","year":"2004","unstructured":"Suzuki T, Uchida H, Tanaka KF, Nomura K, Takano H, Tanabe A, et al. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol. 2004;7(2):133\u201342.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"6717_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.pnpbp.2003.11.006","volume":"28","author":"T Suzuki","year":"2004","unstructured":"Suzuki T, Uchida H, Watanabe K, Yagi G, Kashima H. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(2):361\u20139.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"6717_CR17","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1176\/appi.ajp.2011.10060908","volume":"168","author":"SM Essock","year":"2011","unstructured":"Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011;168(7):702\u20138.","journal-title":"Am J Psychiatry"},{"key":"6717_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.schres.2024.06.001","volume":"270","author":"O K\u00f6hler-Forsberg","year":"2024","unstructured":"K\u00f6hler-Forsberg O, H\u00f8jlund M, Rohde C, Kemp AF, Gregersen AT, Mellentin AI, et al. Efficacy and acceptability of interventions to reduce antipsychotic polypharmacy: A systematic review and meta-analysis of randomized clinical trials. Schizophr Res. 2024;270:135\u201343.","journal-title":"Schizophr Res"},{"issue":"5","key":"6717_CR19","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0004867416641195","volume":"50","author":"C Galletly","year":"2016","unstructured":"Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and new Zealand college of psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410\u201372.","journal-title":"Aust N Z J Psychiatry"},{"issue":"11","key":"6717_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/2045125318781475","volume":"8","author":"PM Haddad","year":"2018","unstructured":"Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8(11):303\u201318.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"3","key":"6717_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa0806994","volume":"360","author":"WA Ray","year":"2009","unstructured":"Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225\u201335.","journal-title":"N Engl J Med"},{"issue":"1\u20133","key":"6717_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.schres.2014.06.035","volume":"158","author":"AP Husa","year":"2014","unstructured":"Husa AP, Rannikko I, Moilanen J, Haapea M, Murray GK, Barnett J, et al. Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia - An observational 9-year follow-up study. Schizophr Res. 2014;158(1\u20133):134\u201341.","journal-title":"Schizophr Res"},{"issue":"6","key":"6717_CR23","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/archgenpsychiatry.2011.2","volume":"68","author":"DL Foley","year":"2011","unstructured":"Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry. 2011;68(6):609\u201316.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"6717_CR24","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12888-021-03355-3","volume":"21","author":"LM Gr\u00fcnwald","year":"2021","unstructured":"Gr\u00fcnwald LM, Duddy C, Byng R, Crellin N, Moncrieff J. The role of trust and hope in antipsychotic medication reviews between gps and service users a realist review. BMC Psychiatry. 2021;21(1):390.","journal-title":"BMC Psychiatry"},{"key":"6717_CR25","doi-asserted-by":"crossref","unstructured":"Fond G, Boyer L, Favez M, Brunel L, Aouizerate B, Berna F, et al. Medication and aggressiveness in real-world schizophrenia. Psychopharmacology. 2016;233(4):571\u20138. Results from the FACE-SZ dataset.","DOI":"10.1007\/s00213-015-4167-8"},{"key":"6717_CR26","first-page":"1885","volume":"11","author":"B Dell\u2019Osso","year":"2015","unstructured":"Dell\u2019Osso B, Albert U, Atti AR, Carmassi C, Carr\u00e0 G, Cosci F, et al. Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. Neuropsychiatr Dis Treat. 2015;11:1885\u2013909.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"6717_CR27","doi-asserted-by":"crossref","unstructured":"Blanco C, Han B, Jones CM, Johnson K, Compton WM. Prevalence and correlates of benzodiazepine use, misuse, and use disorders among adults in the united States. J Clin Psychiatry. 2018;79(6).","DOI":"10.4088\/JCP.18m12174"},{"issue":"6","key":"6717_CR28","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1176\/appi.ajp.2015.15050618","volume":"173","author":"J Tiihonen","year":"2016","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Torniainen M, Alexanderson K, Tanskanen A. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational Follow-Up study. Am J Psychiatry. 2016;173(6):600\u20136.","journal-title":"Am J Psychiatry"},{"key":"6717_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ajp.2019.07.041","volume":"44","author":"HSS Shilpa","year":"2019","unstructured":"Shilpa HSS, Kumar NN, Maheswari E, Virupaksha HS, Subeesh V, Saraswathy GR, et al. Deprescribing of benzodiazepines and Z-drugs amongst the psychiatric patients of a tertiary care hospital. Asian J Psychiatry. 2019;44:189\u201394.","journal-title":"Asian J Psychiatry"},{"issue":"2","key":"6717_CR30","first-page":"80","volume":"33","author":"AM Lupu","year":"2021","unstructured":"Lupu AM, MacCamy KL, Gannon JM, Brar JS, Chengappa KNR. Less is more: deprescribing anticholinergic medications in persons with severe mental illness. Ann Clin Psychiatry. 2021;33(2):80\u201392.","journal-title":"Ann Clin Psychiatry"},{"issue":"Suppl 1","key":"6717_CR31","first-page":"A45","volume":"24","author":"FB Busquets","year":"2017","unstructured":"Busquets FB, Galindo VB, Ayala MU, Su\u00e1rez JA, Riba RF, Isanda MR. CP-103\u2005Deprescribing medication in geriatric patients with chronic psychiatric diseases. Eur J Hosp Pharm. 2017;24(Suppl 1):A45\u20136.","journal-title":"Eur J Hosp Pharm"},{"issue":"10","key":"6717_CR32","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/j.sapharm.2020.12.010","volume":"17","author":"JM Gannon","year":"2021","unstructured":"Gannon JM, Lupu A, Brar J, Brandt M, Zawacki S, John S, et al. Deprescribing anticholinergic medication in the community mental health setting: A quality improvement initiative. Res Social Administrative Pharm. 2021;17(10):1841\u20136.","journal-title":"Res Social Administrative Pharm"},{"issue":"4","key":"6717_CR33","doi-asserted-by":"publisher","first-page":"e0151066","DOI":"10.1371\/journal.pone.0151066","volume":"11","author":"NJ Ailabouni","year":"2016","unstructured":"Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and enablers of deprescribing: A general practitioner perspective. PLoS ONE. 2016;11(4):e0151066.","journal-title":"PLoS ONE"},{"issue":"2","key":"6717_CR34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/wps.20412","volume":"16","author":"M Slade","year":"2017","unstructured":"Slade M. Implementing shared decision making in routine mental health care. World Psychiatry. 2017;16(2):146\u201353.","journal-title":"World Psychiatry"},{"issue":"1","key":"6717_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1573400514666180531095016","volume":"14","author":"DJ Cahill","year":"2018","unstructured":"Cahill DJ, Gupta S. Deprescribing for psychiatry: the right prescription?? Curr Psychiatry Reviews. 2018;14(1):4\u201311.","journal-title":"Curr Psychiatry Reviews"},{"issue":"2","key":"6717_CR36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.12968\/jprp.2021.3.2.60","volume":"3","author":"N Tomova","year":"2021","unstructured":"Tomova N, Hale A, Kruschandl M. Deprescribing in mental health: pragmatic steps for a better quality of life. J Prescribing Pract. 2021;3(2):60\u20136.","journal-title":"J Prescribing Pract"},{"issue":"4","key":"6717_CR37","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"6717_CR38","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s40266-016-0410-1","volume":"33","author":"E Reeve","year":"2016","unstructured":"Reeve E, Low LF, Shakib S, Hilmer SN. Development and validation of the revised patients\u2019 attitudes towards deprescribing (rPATD) questionnaire: versions for older adults and caregivers. Drugs Aging. 2016;33(12):913\u201328.","journal-title":"Drugs Aging"},{"issue":"1","key":"6717_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bcpt.13952","volume":"134","author":"C Lundby","year":"2024","unstructured":"Lundby C, Nielsen M, Simonsen T, Galsgaard S, Haastrup MB, Ravn-Nielsen LV, et al. Attitudes towards deprescribing in geriatric psychiatry: A survey among older psychiatric outpatients. Basic Clin Pharmacol Toxicol. 2024;134(1):97\u2013106.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"8","key":"6717_CR40","first-page":"527","volume":"61","author":"N Frankowski","year":"2019","unstructured":"Frankowski N, Grootens KP, van der Stelt CA, Noort A, van Marum RJ. [\u2018You tell me, you are the Doctor\u2019; patients on long-term psychiatric residences about their medication]. Tijdschr Psychiatr. 2019;61(8):527\u201335.","journal-title":"Tijdschr Psychiatr"},{"issue":"5","key":"6717_CR41","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1093\/gerona\/glab222","volume":"77","author":"KR Weir","year":"2022","unstructured":"Weir KR, Ailabouni NJ, Schneider CR, Hilmer SN, Reeve E. Consumer attitudes towards deprescribing: A systematic review and Meta-Analysis. J Gerontol Biol Sci Med Sci. 2022;77(5):1020\u201334.","journal-title":"J Gerontol Biol Sci Med Sci"},{"key":"6717_CR42","volume-title":"Sample size determination in health studies: a practical manual \/ S. K. Lwanga and S. Lemeshow","author":"SK Lwanga","year":"1991","unstructured":"Lwanga SK, Lemeshow S, World Health O. Sample size determination in health studies: a practical manual \/ S. K. Lwanga and S. Lemeshow. Geneva: World Health Organization. 1991."},{"issue":"null","key":"6717_CR43","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.2147\/PPA.S323846","volume":"15","author":"I Bu\u017ean\u010di\u0107","year":"2021","unstructured":"Bu\u017ean\u010di\u0107 I, Dragovi\u0107 P, Pejakovi\u0107 TI, Markulin L, Ortner-Had\u017eiabdi\u0107 M. Exploring patients\u2019 attitudes toward deprescribing and their perception of pharmacist involvement in a European country: A Cross-Sectional study. Patient Prefer Adherence. 2021;15(null):2197\u2013208.","journal-title":"Patient Prefer Adherence"},{"key":"6717_CR44","doi-asserted-by":"publisher","first-page":"795043","DOI":"10.3389\/fpubh.2022.795043","volume":"10","author":"MP Oktora","year":"2022","unstructured":"Oktora MP, Edwina AE, Denig P. Differences in older patients\u2019 attitudes toward deprescribing at contextual and individual level. Front Public Health. 2022;10:795043.","journal-title":"Front Public Health"},{"issue":"3","key":"6717_CR45","doi-asserted-by":"publisher","first-page":"e0149984","DOI":"10.1371\/journal.pone.0149984","volume":"11","author":"K Potter","year":"2016","unstructured":"Potter K, Flicker L, Page A, Etherton-Beer C. Deprescribing in frail older people: A randomised controlled trial. PLoS ONE. 2016;11(3):e0149984.","journal-title":"PLoS ONE"},{"issue":"6","key":"6717_CR46","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/jgs.15804","volume":"67","author":"E Reeve","year":"2019","unstructured":"Reeve E, Low LF, Hilmer SN. Attitudes of older adults and caregivers in Australia toward deprescribing. J Am Geriatr Soc. 2019;67(6):1204\u201310.","journal-title":"J Am Geriatr Soc"},{"key":"6717_CR47","doi-asserted-by":"publisher","first-page":"204209861881656","DOI":"10.1177\/2042098618816562","volume":"10","author":"D Gnjidic","year":"2019","unstructured":"Gnjidic D, Ong HMM, Leung C, Jansen J, Reeve E. The impact of in hospital patient-education intervention on older People\u2019s attitudes and intention to have their benzodiazepines deprescribed: a feasibility study. Ther Adv Drug Saf. 2019;10:2042098618816562.","journal-title":"Ther Adv Drug Saf"},{"key":"6717_CR48","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2147\/NDT.S139557","volume":"13","author":"M Sajatovic","year":"2017","unstructured":"Sajatovic M, DiBiasi F, Legacy SN. Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic review. Neuropsychiatr Dis Treat. 2017;13:2285\u201396.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"6717_CR49","doi-asserted-by":"publisher","first-page":"374","DOI":"10.4103\/0976-3147.139989","volume":"5","author":"S Grover","year":"2014","unstructured":"Grover S, Chakrabarti S, Sharma A, Tyagi S. Attitudes toward psychotropic medications among patients with chronic psychiatric disorders and their family caregivers. J Neurosci Rural Pract. 2014;5(4):374\u201383.","journal-title":"J Neurosci Rural Pract"},{"key":"6717_CR50","doi-asserted-by":"publisher","first-page":"100178","DOI":"10.1016\/j.rcsop.2022.100178","volume":"7","author":"P Ghosh","year":"2022","unstructured":"Ghosh P, Balasundaram S, Sankaran A, Chandrasekaran V, Sarkar S, Choudhury S. Factors associated with medication non-adherence among patients with severe mental disorder - A cross sectional study in a tertiary care centre. Exploratory Res Clin Social Pharm. 2022;7:100178.","journal-title":"Exploratory Res Clin Social Pharm"},{"issue":"6","key":"6717_CR51","doi-asserted-by":"publisher","first-page":"e5968","DOI":"10.1111\/hsc.14029","volume":"30","author":"TNT Bui","year":"2022","unstructured":"Bui TNT, Hotham E, Loughhead M, McMillan SS, Procter N, Poole K, et al. Exploring mental health clients\u2019 current medication knowledge, beliefs and experience with healthcare providers in the community in South Australia. Health Soc Care Community. 2022;30(6):e5968\u201378.","journal-title":"Health Soc Care Community"},{"key":"6717_CR52","doi-asserted-by":"crossref","unstructured":"Chauhan N, Chakrabarti S, Grover S. Attitudes to Medication\u2014Treatment among patients and caregivers: A longitudinal comparison of bipolar disorder and schizophrenia from India. J Clin Psychopharmacol. 2020;40(1).","DOI":"10.1097\/JCP.0000000000001144"},{"issue":"7","key":"6717_CR53","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/00019442-200507000-00005","volume":"13","author":"L Ayalon","year":"2005","unstructured":"Ayalon L, Are\u00e1n PA, Alvidrez J. Adherence to antidepressant medications in black and Latino elderly patients. Am J Geriatr Psychiatry. 2005;13(7):572\u201380.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"6717_CR54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13643-020-1274-3","volume":"9","author":"A Semahegn","year":"2020","unstructured":"Semahegn A, Torpey K, Manu A, Assefa N, Tesfaye G, Ankomah A. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Syst Rev. 2020;9(1):17.","journal-title":"Syst Rev"},{"issue":"5","key":"6717_CR55","doi-asserted-by":"publisher","first-page":"275","DOI":"10.9740\/mhc.2020.09.275","volume":"10","author":"N Vadiei","year":"2020","unstructured":"Vadiei N, Chien J, Enwereji J, Myslinski B, Guzman A. Start low, go fast? Antipsychotic Titration patterns at an inpatient psychiatric hospital. Ment Health Clin. 2020;10(5):275\u201381.","journal-title":"Ment Health Clin"},{"issue":"15\u201316","key":"6717_CR56","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1111\/j.1365-2702.2010.03659.x","volume":"20","author":"YL Chiang","year":"2011","unstructured":"Chiang YL, Klainin-Yobas P, Ignacio J, Chng CM. The impact of antipsychotic side effects on attitudes towards medication in people with schizophrenia and related disorders. J Clin Nurs. 2011;20(15\u201316):2172\u201382.","journal-title":"J Clin Nurs"},{"issue":"1","key":"6717_CR57","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11096-013-9871-z","volume":"36","author":"E Reeve","year":"2014","unstructured":"Reeve E, Wiese MD. Benefits of deprescribing on patients\u2019 adherence to medications. Int J Clin Pharm. 2014;36(1):26\u20139.","journal-title":"Int J Clin Pharm"},{"issue":"10","key":"6717_CR58","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1097\/JGP.0b013e318181f992","volume":"16","author":"EL O\u2019Neal","year":"2008","unstructured":"O\u2019Neal EL, Adams JR, McHugo GJ, Van Citters AD, Drake RE, Bartels SJ. Preferences of older and younger adults with serious mental illness for involvement in Decision-Making in medical and psychiatric settings. Am J Geriatric Psychiatry. 2008;16(10):826\u201333.","journal-title":"Am J Geriatric Psychiatry"},{"issue":"1","key":"6717_CR59","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12888-021-03137-x","volume":"21","author":"I Mundal","year":"2021","unstructured":"Mundal I, Lara-Cabrera ML, Betancort M, De las Cuevas C. Exploring patterns in psychiatric outpatients\u2019 preferences for involvement in decision-making: a latent class analysis approach. BMC Psychiatry. 2021;21(1):133.","journal-title":"BMC Psychiatry"},{"issue":"2","key":"6717_CR60","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/jpm.12671","volume":"28","author":"K McKay","year":"2021","unstructured":"McKay K, Ariss J, Rudnick A. RAISe-ing awareness: Person-centred care in coercive mental health care environments-A scoping review and framework development. J Psychiatr Ment Health Nurs. 2021;28(2):251\u201360.","journal-title":"J Psychiatr Ment Health Nurs"},{"issue":"1","key":"6717_CR61","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2174\/1573400514666180612092055","volume":"14","author":"S Gupta","year":"2018","unstructured":"Gupta S, Steingard S, Garcia Aracena EF, Fathy H. Deprescribing antipsychotic medications in psychotic disorders: how and why? Curr Psychiatry Reviews. 2018;14(1):26\u201332.","journal-title":"Curr Psychiatry Reviews"},{"key":"6717_CR62","volume-title":"The Maudsley deprescribing guidelines: antidepressants, benzodiazepines","author":"M Horowitz","year":"2024","unstructured":"Horowitz M, Taylor DM. The Maudsley deprescribing guidelines: antidepressants, benzodiazepines. Gabapentinoids and Z-drugs: Wiley; 2024."},{"issue":"6","key":"6717_CR63","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/bcpt.13867","volume":"133","author":"J Lagreula","year":"2023","unstructured":"Lagreula J, Dagenais-Beaul\u00e9 V, de Timary P, Elens L, Dalleur O. Prescribing and deprescribing trends in schizophrenia: an overview of inpatients in Belgium and in the Canadian Province of Qu\u00e9bec. Basic Clin Pharmacol Toxicol. 2023;133(6):691\u2013702.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"8","key":"6717_CR64","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1136\/bmjqs-2019-010033","volume":"29","author":"ER Barnett","year":"2020","unstructured":"Barnett ER, Trepman AZ, Fuson HA, Acquilano SC, McLaren JL, Woloshin S, et al. Deprescribing psychotropic medications in children: results of a National qualitative study. BMJ Qual Saf. 2020;29(8):655\u201363.","journal-title":"BMJ Qual Saf"},{"issue":"3","key":"6717_CR65","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40596-019-01177-w","volume":"44","author":"L Hutchison","year":"2020","unstructured":"Hutchison L, Clark M, Gnerre C, Rollhaus E, Eisenberg R, Mowrey W. Child and adolescent psychiatry trainees\u2019 attitudes toward prescribing and managing psychotropic medications. Acad Psychiatry. 2020;44(3):277\u201382.","journal-title":"Acad Psychiatry"},{"issue":"4","key":"6717_CR66","doi-asserted-by":"publisher","first-page":"e0154449","DOI":"10.1371\/journal.pone.0154449","volume":"11","author":"H Barratt","year":"2016","unstructured":"Barratt H, Rojas-Garc\u00eda A, Clarke K, Moore A, Whittington C, Stockton S, et al. Epidemiology of mental health attendances at emergency departments: systematic review and Meta-Analysis. PLoS ONE. 2016;11(4):e0154449.","journal-title":"PLoS ONE"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06717-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-06717-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06717-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T03:20:10Z","timestamp":1742786410000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-06717-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6717"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-06717-3","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from Central Adelaide Local Health Network Human Research Ethics Committee (CALHN HREC) and Barossa Hills Fleurieu Local Health Network (BHFLHN HREC) in accordance with the Declaration of Helsinki. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr Reeve receives royalties for co-authoring a chapter on deprescribing in UpToDate. The authors declare no other potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"269"}}